A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Suptavumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms NURSERY Pre-Term
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 According to a Regeneron Pharmaceuticals media release, based on results from this study Regeneron plans to discontinue further clinical development of this antibody.
    • 14 Aug 2017 Status changed from active, no longer recruiting to completed, according to a Regeneron Pharmaceuticals media release.
    • 14 Aug 2017 According to a Regeneron Pharmaceuticals media release, data from the study will be presented at a future medical congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top